FIND-CKD (2026) — Trial Summary

FIND-CKD (2026): Phase 3 randomized, double-blind, placebo-controlled trial of finerenone (10 or 20 mg daily) versus placebo in 1,584 adults without diabetes who had CKD (eGFR 25 to <90 mL/min/1.73 m²) and albuminuria (UACR 200 to ≤3500 mg/g) on a renin-angiotensin system inhibitor (NCT05047263). Pr

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.